Macrophagic Sclerostin Loop2‐ApoER2 Interaction Required by Sclerostin for Cardiovascular Protective Action

Therapeutic antibody against sclerostin loop2 promoted bone formation in postmenopausal osteoporosis but caused severe cardiovascular events in clinical applications. The studies of atherosclerosis and aortic aneurysm in SOST<sup>ki</sup>.ApoE<sup>-/-</sup> mice and sost<sup>-/-</sup>.ApoE<sup>-/-</sup> mice collectively indicated the cardiovascular protective action of sclerostin. However, how sclerostin exerts cardiovascular protective action remains unclear. In this study, ApoER2 (LRP8) is notably identified as a novel transmembrane receptor for sclerostin in macrophages. Mechanistically, blockade of macrophagic sclerostin loop2-ApoER2 interaction attenuates the suppressive effects of sclerostin on NF-κB nuclear translocation, phosphorylation, and mRNA expression in macrophages, reduces the promotive effects of sclerostin on macrophage conversion to anti-inflammatory phenotypes, and inhibits the preventive effects of sclerostin on atherosclerosis and aortic aneurysm in ApoE<sup>-/-</sup> mice. Together, macrophagic sclerostin loop2-ApoER2 interaction is required by sclerostin to suppress inflammatory responses, atherosclerosis, and aortic aneurysm in ApoE<sup>-/-</sup> mice. Sclerostin plays a compensatory protective role in the cardiovascular system when ApoE is absent or mutated. Translationally, it provided critical pre-clinical evidence regarding the prediction of cardiovascular risk populations (e.g., APOE variants) for the marketed antibody against sclerostin loop2. Importantly, targeting sclerostin while preserving macrophagic sclerostin loop2-ApoER2 interaction would offer the next generation of precise sclerostin inhibition strategy without cardiovascular safety concern, while promoting bone formation.

Authors

Institutions

Publication Details

Journal
Advanced Science
Published
2025-11-23
DOI
https://doi.org/10.1002/advs.202518735
Primary Topic
Bone health and osteoporosis research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Macrophagic Sclerostin Loop2‐ApoER2 Interaction Required by Sclerostin for Cardiovascular Protective Action

Nanxi Li, Sifan Yu, Shi‐Jian Ding, Shenghang Wang et al.
Advanced Science
Bone health and osteoporosis research
article

Macrophagic Sclerostin Loop2‐ApoER2 Interaction Required by Sclerostin for Cardiovascular Protective Action

Nanxi Li, Sifan Yu, Shi‐Jian Ding, Shenghang Wang, Luyao Wang, Jin Liu, Xin Yang, Bao‐Ting Zhang, Haitian Li, Yuying Huang, Hewen Jiang, Meiheng Sun, Yuanyuan Yu, Aiping Lü, Chuanxin Zhong, Zhanghao Li, Xiaoxin Wen, Ge Zhang, Xiaofei Li, Tao Zhang, Ning Zhang, Shu Zhang, Xiang‐Hang Luo, Yihao Zhang, Daqing Ma, Xiaohui Tao, Huarui Zhang, Péter Ferdinandy
article en

Abstract

Therapeutic antibody against sclerostin loop2 promoted bone formation in postmenopausal osteoporosis but caused severe cardiovascular events in clinical applications. The studies of atherosclerosis and aortic aneurysm in SOST<sup>ki</sup>.ApoE<sup>-/-</sup> mice and sost<sup>-/-</sup>.ApoE<sup>-/-</sup> mice collectively indicated the cardiovascular protective action of sclerostin. However, how sclerostin exerts cardiovascular protective action remains unclear. In this study, ApoER2 (LRP8) is notably identified as a novel transmembrane receptor for sclerostin in macrophages. Mechanistically, blockade of macrophagic sclerostin loop2-ApoER2 interaction attenuates the suppressive effects of sclerostin on NF-κB nuclear translocation, phosphorylation, and mRNA expression in macrophages, reduces the promotive effects of sclerostin on macrophage conversion to anti-inflammatory phenotypes, and inhibits the preventive effects of sclerostin on atherosclerosis and aortic aneurysm in ApoE<sup>-/-</sup> mice. Together, macrophagic sclerostin loop2-ApoER2 interaction is required by sclerostin to suppress inflammatory responses, atherosclerosis, and aortic aneurysm in ApoE<sup>-/-</sup> mice. Sclerostin plays a compensatory protective role in the cardiovascular system when ApoE is absent or mutated. Translationally, it provided critical pre-clinical evidence regarding the prediction of cardiovascular risk populations (e.g., APOE variants) for the marketed antibody against sclerostin loop2. Importantly, targeting sclerostin while preserving macrophagic sclerostin loop2-ApoER2 interaction would offer the next generation of precise sclerostin inhibition strategy without cardiovascular safety concern, while promoting bone formation.

Advanced ScienceVol. 13(8)
Semmelweis University (HU), Central South University (CN), Hong Kong Baptist University (HK), City University of Hong Kong (HK), Chinese University of Hong Kong (HK), University of Szeged (HU), Discovery Centre (CA), Air Force Engineering University (CN), Children's Hospital of Zhejiang University (CN), Shanghai Institute of Technical Physics (CN), Chelsea and Westminster Hospital (GB), Xiangya Hospital Central South University (CN)
Openalex Percentile: Top 54%
Bone health and osteoporosis research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.